A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer

Christopher Ryan, Everett E. Vokes, Nicholas J. Vogelzang, Linda Janisch, Ken Kobayashi, Mark J. Ratain

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: The optimal schedule of administration of suramin has not been well defined. The purpose of this study was to determine the maximum tolerated dose and toxicities of suramin when administered using a fixed dosing scheme on a once- or twice-monthly schedule. Methods: A total of 40 patients were treated on this phase I dose-escalation study employing a once-monthly (day 1 of each 28-day cycle) and a twice-monthly (days 1 and 8 of each 28-day cycle) schedule. Results: The most common dose-limiting events included fatigue, neuropathy, and anorexia. We identified the 1440 mg/m2 dose level to be the maximal tolerated dose for both schedules, with 83% of patients developing dose-limiting toxicity (DLT) on the twice-monthly schedule, and 67% developing DLT on the monthly schedule. At the 1200 mg/m2 dose level, only 25% developed DLT on the twice-monthly schedule and 33% developed DLT on the monthly schedule. Trough suramin levels gradually increased with higher dose levels but fell well below the putative toxic concentration of 350 μg/ml. Conclusion: Suramin can be safely administered using a monthly schedule without using plasma concentrations to guide dosing.

Original languageEnglish (US)
Pages (from-to)1-5
Number of pages5
JournalCancer Chemotherapy and Pharmacology
Volume50
Issue number1
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Suramin
Toxicity
Appointments and Schedules
Neoplasms
Maximum Tolerated Dose
Poisons
Fatigue of materials
Plasmas
Anorexia
Fatigue

Keywords

  • Adaptive control
  • Clinical trial
  • Phase I
  • Suramin

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer. / Ryan, Christopher; Vokes, Everett E.; Vogelzang, Nicholas J.; Janisch, Linda; Kobayashi, Ken; Ratain, Mark J.

In: Cancer Chemotherapy and Pharmacology, Vol. 50, No. 1, 2002, p. 1-5.

Research output: Contribution to journalArticle

Ryan, Christopher ; Vokes, Everett E. ; Vogelzang, Nicholas J. ; Janisch, Linda ; Kobayashi, Ken ; Ratain, Mark J. / A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer. In: Cancer Chemotherapy and Pharmacology. 2002 ; Vol. 50, No. 1. pp. 1-5.
@article{e3e5f98cbd5540f49b052618254e81ed,
title = "A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer",
abstract = "Purpose: The optimal schedule of administration of suramin has not been well defined. The purpose of this study was to determine the maximum tolerated dose and toxicities of suramin when administered using a fixed dosing scheme on a once- or twice-monthly schedule. Methods: A total of 40 patients were treated on this phase I dose-escalation study employing a once-monthly (day 1 of each 28-day cycle) and a twice-monthly (days 1 and 8 of each 28-day cycle) schedule. Results: The most common dose-limiting events included fatigue, neuropathy, and anorexia. We identified the 1440 mg/m2 dose level to be the maximal tolerated dose for both schedules, with 83{\%} of patients developing dose-limiting toxicity (DLT) on the twice-monthly schedule, and 67{\%} developing DLT on the monthly schedule. At the 1200 mg/m2 dose level, only 25{\%} developed DLT on the twice-monthly schedule and 33{\%} developed DLT on the monthly schedule. Trough suramin levels gradually increased with higher dose levels but fell well below the putative toxic concentration of 350 μg/ml. Conclusion: Suramin can be safely administered using a monthly schedule without using plasma concentrations to guide dosing.",
keywords = "Adaptive control, Clinical trial, Phase I, Suramin",
author = "Christopher Ryan and Vokes, {Everett E.} and Vogelzang, {Nicholas J.} and Linda Janisch and Ken Kobayashi and Ratain, {Mark J.}",
year = "2002",
doi = "10.1007/s00280-002-0458-y",
language = "English (US)",
volume = "50",
pages = "1--5",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer

AU - Ryan, Christopher

AU - Vokes, Everett E.

AU - Vogelzang, Nicholas J.

AU - Janisch, Linda

AU - Kobayashi, Ken

AU - Ratain, Mark J.

PY - 2002

Y1 - 2002

N2 - Purpose: The optimal schedule of administration of suramin has not been well defined. The purpose of this study was to determine the maximum tolerated dose and toxicities of suramin when administered using a fixed dosing scheme on a once- or twice-monthly schedule. Methods: A total of 40 patients were treated on this phase I dose-escalation study employing a once-monthly (day 1 of each 28-day cycle) and a twice-monthly (days 1 and 8 of each 28-day cycle) schedule. Results: The most common dose-limiting events included fatigue, neuropathy, and anorexia. We identified the 1440 mg/m2 dose level to be the maximal tolerated dose for both schedules, with 83% of patients developing dose-limiting toxicity (DLT) on the twice-monthly schedule, and 67% developing DLT on the monthly schedule. At the 1200 mg/m2 dose level, only 25% developed DLT on the twice-monthly schedule and 33% developed DLT on the monthly schedule. Trough suramin levels gradually increased with higher dose levels but fell well below the putative toxic concentration of 350 μg/ml. Conclusion: Suramin can be safely administered using a monthly schedule without using plasma concentrations to guide dosing.

AB - Purpose: The optimal schedule of administration of suramin has not been well defined. The purpose of this study was to determine the maximum tolerated dose and toxicities of suramin when administered using a fixed dosing scheme on a once- or twice-monthly schedule. Methods: A total of 40 patients were treated on this phase I dose-escalation study employing a once-monthly (day 1 of each 28-day cycle) and a twice-monthly (days 1 and 8 of each 28-day cycle) schedule. Results: The most common dose-limiting events included fatigue, neuropathy, and anorexia. We identified the 1440 mg/m2 dose level to be the maximal tolerated dose for both schedules, with 83% of patients developing dose-limiting toxicity (DLT) on the twice-monthly schedule, and 67% developing DLT on the monthly schedule. At the 1200 mg/m2 dose level, only 25% developed DLT on the twice-monthly schedule and 33% developed DLT on the monthly schedule. Trough suramin levels gradually increased with higher dose levels but fell well below the putative toxic concentration of 350 μg/ml. Conclusion: Suramin can be safely administered using a monthly schedule without using plasma concentrations to guide dosing.

KW - Adaptive control

KW - Clinical trial

KW - Phase I

KW - Suramin

UR - http://www.scopus.com/inward/record.url?scp=0036305931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036305931&partnerID=8YFLogxK

U2 - 10.1007/s00280-002-0458-y

DO - 10.1007/s00280-002-0458-y

M3 - Article

VL - 50

SP - 1

EP - 5

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1

ER -